ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0256

Anti-TNF Therapy as a Potential Risk of Leishmania Infections

Gloria Albaladejo Paredes1, Alicia Pérez González1, Esther Monleón Acosta1, Jose Andrés Rodríguez Fernández1, Pedro José Manuel Hernández1, Carlos Fernández Díaz1, María Rosario Oliva Ruíz1, Jose María Andreu Ubero2, Paloma Valentina Castillo Dayer2, Edgar Soriano Navarro3, David Pérez Parra4, Claudia Alejandra Capozzi2, María Rocío González Molina5, José Francisco Orts Paco6, José Pablo Serrano Serra6 and Vicente Cogolludo Campillo2, 1Hospital Universitario Santa Lucía, CARTAGENA, Spain, 2Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain, 3Hospital Universitario Santa Lucía, Murcia, Murcia, Spain, 4Hospital Universitario Santa Lucía, Murcia, 5Hospital Reina Sofía, Murcia, Murcia, Spain, 6Hospital Universitario Reina Sofía, Murcia, Murcia, Spain

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, Epidemiology, Infection, Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Leishmaniasis is an infectious disease caused by protozoon that occurs endemically in the Mediterranean Basin and South America and can affects to travellers to this areas (Figure 1). Leishmaniasis disease can manifest as cutaneous (CL), mucocutaneous (ML) or visceral (VL) disease (1). The number of infections produced by leishmaniasis in patients being treated with anti-TNF inhibitor drugs has increased in the last recent years (1,2) 
The aim of the present study was to evaluate the risk of leishmania infection as well as its evolution in immunosuppressed patients with anti-TNF therapy in leishmania endemic areas.

Methods: A descriptive, retrospective, multi-center study was performed in two hospital in the southeast of Spain. Data was collected from a microbiology database from patients with positive biopsy for leishmaniasis from january 2020 to december 2023. Variables analyzed were: age, gender, presence of immunosuppressive disease and presence of biological treatment (BT) at the time of diagnosis of leishmaniasis. The treatment received for leishmaniasis and the disease outcome were also reviewed.

Results: A total of 25 patients with leishmaniasis were included, whose characteristics are summarized in a table (Table 1). Of the 25 patients,  20 were on antiTNF therapy and one of them was receiving antiL17 treatment (Figure 1), however this patient had received antiTNF recently. Most patients with antiTNF treatment had CL (92%) and 2 patients had VL (2%). Immunosuppressive treatment was stopped in all patients when they were diagnosed with leismaniasis, except for 7 patients with CL. Five patients who did not discontinue antiTNF had primary failure to local treatment and recurrence of infection. These five patients subsequently stopped antiTNF and four of them required amphotericin B intravenous until remission infection and another one received surgery with remission. Of these seven patients with primary faillure to leishmaniasis treatment, four reincorporated antiTNF treatment.

In the present study, in total nine patients reintroduced treatment with antiTNF therapy when they were in remission of leishmaniasis and continue in remission 12 months after reintroducing antiTNF therapy.

Conclusion: AntiTNF therapy is a potential risk for leishmaniasis disease in endemic areas. Our treatment recommendations included discontinuations of anti TNF until recovery and systemic treatment. The risk of restarting anti-TNF after recovery is unclear.

References:

1. Bosch-Nicolau P et al.Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis. 2019
2. Hammarström H et al. Leishmania infantum infection after visiting southern Spain in patients on biological treatment; an observational, longitudinal, cohort study. Travel Med Infect Dis. 2023

Supporting image 1

Table 1. ADA: Adalimumab, Am intralocal: Antimonial intralocal, AS: anquilosis spondilitis, BM: bone marrow, CERTO: Certolizumab, IBD: inflammatory bowel disease, IFX: Infliximab, JIA: Juvenile Idiopathic Arthritis, LD: Leishmaniasis Disease, L-AmB: liposomal amphotericine B , M: Man, PsA: Psoriatic Arthritis, RA: Reumatoid Arthritis, SECU: Secukinumab, SpA: Spondiloartritis, W: Woman

Supporting image 2

Figure 1. Leishmaniasis endemic areas. Fountain: WHO. 2005

Supporting image 3

Figure 2. Biological treatment in patient with leishmaniasis infection


Disclosures: G. Albaladejo Paredes: None; A. Pérez González: None; E. Monleón Acosta: None; J. Rodríguez Fernández: None; P. Manuel Hernández: None; C. Fernández Díaz: None; M. Oliva Ruíz: None; J. Andreu Ubero: None; P. Castillo Dayer: None; E. Soriano Navarro: None; D. Pérez Parra: None; C. Capozzi: None; M. González Molina: None; J. Orts Paco: None; J. Serrano Serra: None; V. Cogolludo Campillo: None.

To cite this abstract in AMA style:

Albaladejo Paredes G, Pérez González A, Monleón Acosta E, Rodríguez Fernández J, Manuel Hernández P, Fernández Díaz C, Oliva Ruíz M, Andreu Ubero J, Castillo Dayer P, Soriano Navarro E, Pérez Parra D, Capozzi C, González Molina M, Orts Paco J, Serrano Serra J, Cogolludo Campillo V. Anti-TNF Therapy as a Potential Risk of Leishmania Infections [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/anti-tnf-therapy-as-a-potential-risk-of-leishmania-infections/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-tnf-therapy-as-a-potential-risk-of-leishmania-infections/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology